Concurrent rise seen in fall-related mortality in older adults in the United States from 1999 to 2017
Significant reduction found in risk for disease progression/death for C+R versus placebo and rituximab
Increased exposure linked to significantly increased rates of incident keratinocyte carcinoma, melanoma in adults ≥66 years
Mortality risk lower with PDE5i treatment versus alprostadil treatment; similar links seen for MI, heart failure, CV mortality risks
However, authors warn that stagnation and possible increase in more recent years may indicate reversal of trend
Twenty-five percent experienced CVD event during follow-up; risk up for ß-blocker use but not with calcium channel blockers, diuretics
